Anixa Biosciences, Inc. (ANIX) 2010年年度报告「NASDAQ」.pdf

1、UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWASHINGTON,D.C.20549 FORM 10-K xANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACT OF1934 For the fiscal year ended October 31,2010 or TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d)OF THE SECURITIES EXCHANGE ACTOF 1934 For th

2、e transition period from _ to _ Commission file number:0-11254 COPYTELE,INC.(Exact Name of Registrant as Specified in its Charter)Delaware 11-2622630(State or Other Jurisdiction of Incorporation or Organization)(I.R.S.Employer Identification No.)900 Walt Whitman RoadMelville,NY 11747(631)549-5900(Ad

3、dress,Including Zip Code,and Telephone Number,Including Area Code,of Registrants Principal Executive Offices)Securities registered pursuant to Section 12(b)of the Act:NoneSecurities registered pursuant to Section 12(g)of the Act:Common Stock,$.01 par value Indicate by check mark if the registrant is

4、 a well-known seasoned issuer,as defined in Rule 405 of the Securities Act.Yes _ No x Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d)of the Act.Yes _ No x Indicate by check mark whether the registrant:(1)has filed all reports required

5、to be filed by Section 13 or 15(d)of the Securities ExchangeAct of 1934 during the preceding 12 months(or for such shorter period that the registrant was required to file such reports),and(2)has beensubject to such filing requirements for the past 90 days.Yes x No _ Indicate by check mark whether th

6、e registrant has submitted electronically and posted on its corporate Website,if any,every Interactive DataFile required to be submitted and posted pursuant to Rule 405 of Regulation S-T(232.405 of this chapter)during the preceding 12 months(or for such shorter period that the registrant was require